Selected Grants
Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Visceral Fat, Lipid Metabolites, and Liver Injury in Young Women
ResearchCo Investigator · Awarded by University of California - San Francisco · 2023 - 2028Genomic Imprinting in the Development of NAFLD
ResearchSignificant Contributor · Awarded by National Institutes of Health · 2024 - 2028Bayer Abbreviated MRI for HCC Screening in Cirrhotic Patients (FAST-MRI).
Clinical TrialPrincipal Investigator · Awarded by Icahn School of Medicine at Mount Sinai · 2023 - 2027MAD05 MGL-3196 on liver PDFF and stiffness (measured by MR Elastography) in a NAFLD population
ResearchPrincipal Investigator · Awarded by Madrigal Pharmaceuticals · 2022 - 2026Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2021 - 2026Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Visceral Fat, Lipid Metabolites, and Liver Injury in Young Women
ResearchCo Investigator · Awarded by University of California - San Francisco · 2023 - 2028Genomic Imprinting in the Development of NAFLD
ResearchSignificant Contributor · Awarded by National Institutes of Health · 2024 - 2028Bayer Abbreviated MRI for HCC Screening in Cirrhotic Patients (FAST-MRI).
Clinical TrialPrincipal Investigator · Awarded by Icahn School of Medicine at Mount Sinai · 2023 - 2027MAD05 MGL-3196 on liver PDFF and stiffness (measured by MR Elastography) in a NAFLD population
ResearchPrincipal Investigator · Awarded by Madrigal Pharmaceuticals · 2022 - 2026Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2021 - 2026BOS-580-201, A Phase 2a, randomized, blinded, placebo controlled study of BOS 580 in obese subjects at risk for, or with biopsy confirmed, nonalcoholic steatohepatitis (NASH)
Clinical TrialPrincipal Investigator · Awarded by M3 Wake Research Inc · 2023 - 2026Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH) CRT03
Clinical TrialPrincipal Investigator · Awarded by Corcept Therapeutics, Inc. · 2023 - 2026Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
Clinical TrialPrincipal Investigator · Awarded by Children's Mercy Hospital · 2024 - 20251466-0002 Phase Ib trial to assess safety and tolerability of multiple subcutaneous disease of BI3006337 in patients with overweight or obesity and hepatic steatosis
Clinical TrialPrincipal Investigator · Awarded by M3 Wake Research Inc · 2023 - 2025CQUC398A12201: A randomized, two-arm, placebo-controlled, participant, investigator and sponsor-blinded, proof-of-concept study investigating the efficacy, safety and tolerability of QUC398
Clinical TrialPrincipal Investigator · Awarded by West Clinical Research Inc. · 2023 - 2025Abbreviated MRI for HCC screening in cirrhotic patients
ResearchPrincipal Investigator · Awarded by Icahn School of Medicine at Mount Sinai · 2020 - 2025The effect of CT-388 on body composition (liver fat fraction as measured by MRI-PDFF, and Adiposity as measured by visceral and subcutaneous fat mass, lean mass), in a cohort of obese or overweight pa
ResearchPrincipal Investigator · Awarded by Carmot Therapeutics Inc. · 2023 - 2025Madrigal MGL-3196-14 "A 52-Week Phase 3 Study of Resmetirom (MGL-3196)
ResearchPrincipal Investigator · Awarded by Diabetes & Endocrinology Consultants, PC · 2020 - 2025Imaging Core Lab for Madrigal Protocol MGL-3196-05 (A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis)
ResearchPrincipal Investigator · Awarded by Madrigal Pharmaceuticals · 2019 - 2025Fully Automated High-Throughput Quantitative MRI of the Liver
ResearchPrincipal Investigator · Awarded by University of Wisconsin - Madison · 2022 - 2024A Phase 1b, Open-Label, Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients with Presumed Nonalcoholic Steatohepatitis (NASH)
Clinical TrialPrincipal Investigator · Awarded by Corcept Therapeutics, Inc. · 2021 - 2024Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2024The imaging objective of this study is to determine the effect of MET642 on liver PDFF in patients with nonalcoholic steatohepatitis (NASH).
ResearchPrincipal Investigator · Awarded by Metacrine, Inc · 2020 - 2024Optimizing Preoperative Assessment and Postoperative Management of Bariatric Surgery Patients with Fully Automated, High Throughput and Normalized CT-Based Body Composition Analysis
ResearchAdvisor · Awarded by Radiological Society of North America · 2022 - 2024Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
ResearchInvestigator · Awarded by National Institutes of Health · 2004 - 2024The imaging objectives of this study are to determine the effect of MGL-3196 on liver PDFF and stiffness (measured by MR Elastography) in a NAFLD population for the following:
ResearchPrincipal Investigator · Awarded by Madrigal Pharmaceuticals · 2021 - 2024Photon Counting Computed Tomography for Detection of Small Liver Metastases: Comparison to Conventional and Dual-Energy Systems
ResearchCo Investigator · Awarded by Society of Abdominal Radiology · 2022 - 2024CT-868 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Center Study to Evaluate the Efficacy, Safety, and Tolerability of CT-868 Administered for 26 Weeks to Obese Patients wi
ResearchPrincipal Investigator · Awarded by Carmot Therapeutics Inc. · 2020 - 2023Collaboration for assessment of 129Xe MRI hardware
ResearchPrincipal Investigator · Awarded by Polarean Imaging plc · 2021 - 2023BIO89-100-122 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Clinical TrialPrincipal Investigator · Awarded by M3 Wake Research Inc · 2021 - 2022A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients with Presumed Nonalcoholic Steatohepatitis
ResearchPrincipal Investigator · Awarded by Corcept Therapeutics, Inc. · 2020 - 2022Madrigal MGL-3196-11: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or
ResearchPrincipal Investigator · Awarded by Lucas Research, Inc. · 2020 - 2022A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects with Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH)"
ResearchPrincipal Investigator · Awarded by Enanta Pharmaceuticals, Inc. · 2020 - 2022Determine the effect of GH509 on liver PDFF in a NASH population
ResearchPrincipal Investigator · Awarded by 1Globe Health Institute · 2020 - 2022Determine the effect of CT-001 on liver PDFF and abdominal adiposity in a NAFLD population
ResearchPrincipal Investigator · Awarded by Carmot Therapeutics Inc. · 2020 - 2021A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE DOSES OF HM15211 IN OBESE SUBJECTS WITH NAFLD AND IN SUBJECTS WITH NASH
ResearchPrincipal Investigator · Awarded by Hanmi Pharmaceutical · 2018 - 2020A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of BIO89-100
ResearchPrincipal Investigator · Awarded by M3 Wake Research Inc · 2020 - 20203V2640-CLIN-005 A Phase 2, Multi-Center, Single-Blind, Randomized Placebo Controlled Study of TVB-2640 in Subjects with Non-Alcoholic Steatohepatitis
ResearchPrincipal Investigator · Awarded by Diabetes & Endocrinology Consultants, PC · 2019 - 2020A randomized, open label, phase 1b study to evaluate safety, PK and PD signals of DUR-928 in patients with Non-Alcoholic Steatohepatitis (NASH)
ResearchPrincipal Investigator · Awarded by High Point Clinical Trial Center · 2019 - 2020TAIWANJ JKB 121-001
Clinical TrialCo-Principal Investigator · Awarded by TaiwanJ Pharmaceuticals Co. Ltd · 2015 - 2020CB8025-21845 entitled "A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients with Primary Sclerosing Cholangitis
ResearchPrincipal Investigator · Awarded by CymaBay Therapeutics · 2019 - 2019A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 LIVER FIBROSIS.
ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2018 - 2019A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Histologically Confirmed Nonalcoholic Steatohepatit
Clinical TrialCo-Principal Investigator · Awarded by NGM Biopharmaceuticals · 2015 - 2019LLF580X2102: Analysis of fatty acids as marker of metabolite abnormalities
ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2018 - 2019Development of an Optimized Single Breath Hold, Body MRI Protocol using 4D Dynamic Imaging for Fast, Motion-Free Dyanmic T1-Weighted Imaging
Clinical TrialPrincipal Investigator · Awarded by GE Healthcare · 2015 - 2018Motion-immune neuro and body MRI for challenging patient populations
ResearchCo Investigator · Awarded by National Institutes of Health · 2014 - 2018Body MR Imaging 2017
Clinical TrialPrincipal Investigator · Awarded by Siemens Medical Solutions USA, Inc. · 2017 - 2018Role of Whole Body MRI as a Non-Invasive Technique for Characterizing Disease and Treatment Efficacy in Infantile Onset Pompe disease
Clinical TrialInvestigator · Awarded by Genzyme Corporation · 2016 - 2017Duke Bashir Body Elastography MR
ResearchPrincipal Investigator · Awarded by Siemens Medical Solutions USA, Inc. · 2014 - 2017Randomized, Blinded, Placebo-Controlled Crossover Study Assessing Association Between Gadolinum-Based Contrast Agent Administration and Transient Severe Dyspnea\Arterial Phase Motion
Clinical TrialPrincipal Investigator · Awarded by Guerbet · 2015 - 2017Comparison of image quality features with new image processing methods
Clinical TrialPrincipal Investigator · Awarded by Siemens Medical Solutions USA, Inc. · 2016 - 2017Motion Management Using 4D-MRI for Liver Cancer in Radiation Therapy
ResearchCollaborator · Awarded by National Institutes of Health · 2013 - 2016Body MR Imaging 2015
Clinical TrialPrincipal Investigator · Awarded by Siemens Medical Solutions USA, Inc. · 2015 - 2016Impact of Fructose on Metabolism, Energy Homeostasis and MR biomarkers in NAFLD
ResearchCo Investigator · Awarded by National Institutes of Health · 2012 - 2016Body MR Imaging 2014
Clinical TrialPrincipal Investigator · Awarded by Siemens Medical Solutions USA, Inc. · 2014 - 2016Participation in Observership Program at Duke University
ConferencePrincipal Investigator · Awarded by China International Medical Exchange Foundation · 2015 - 2015Realizing Consistent Combined Hepatic MR Arteriography and Late Arterial Phase Imaging with Eovist
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2013 - 2015MIP1404-1301
Clinical TrialPrincipal Investigator · Awarded by Molecular Insight Pharmaceuticals, Inc. · 2013 - 2014External Relationships
- Journal of Magnetic Resonance Imaging
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.